Intratumor lactate levels reflect HER2 addiction status in HER2-positive breast cancer

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Despite different molecular tumor profiles indicate that human epidermal growth factor receptor 2 (HER2) messenger RNA (mRNA) levels mirror HER2 addiction and trastuzumab benefit in HER2-positive breast cancer (BC), the identification of noninvasive clinical predictors of trastuzumab sensitivity remains an unmet clinical need. In the current study, we investigated whether intratumor lactate levels reflect HER2 addiction and, in turn, trastuzumab susceptibility. Accordingly, the gene expression profiles of transgenic murine BC cell lines expressing the human d16HER2 variant (HER2-addicted) or human full-length HER2 (WTHER2; HER2-nonaddicted) revealed a significant enrichment of glycolysis-related gene pathways in HER2-addicted cells. We studied the metabolic content of 22 human HER2-positive BC by quantitative nuclear magnetic resonance spectroscopy and found that those cases with higher lactate levels were characterized by higher HER2 transcript levels. Moreover, gene expression analyses of HER2-positive BC samples from a TCGA data set revealed a significant enrichment in glycolysis-related pathways in high/HER2-addicted tumors. These data were confirmed by metabolic analyses of human HER2-positive BC cell lines with high or low HER2 transcript levels, which revealed significantly more active glycolytic metabolism in high HER2 transcript than in low HER2 transcript cells. Overall, our results provide evidence for noninvasive intratumor lactate detection as a potential metabolic biomarker of HER2 addiction and trastuzumab response suggesting the possibility to use in vivo imaging to assess lactate levels and, in turn, select HER2-positive BC patients who are more likely to benefit from anti-HER2 treatments.

Original languageEnglish
Pages (from-to)1768-1779
Number of pages12
JournalJournal of Cellular Physiology
Volume234
Issue number2
DOIs
Publication statusPublished - Feb 1 2019

Fingerprint

Lactic Acid
Breast Neoplasms
human ERBB2 protein
Glycolysis
Gene expression
Tumors
Cells
Cell Line
Biomarkers
Transcriptome
Metabolism
Nuclear magnetic resonance spectroscopy
Neoplasms
Mirrors

Keywords

  • breast cancer
  • glycolysis
  • HER2
  • lactate
  • oncogene addiction

ASJC Scopus subject areas

  • Physiology
  • Clinical Biochemistry
  • Cell Biology

Cite this

@article{0a5bf5e7c5884e83a14f8a9d743f857e,
title = "Intratumor lactate levels reflect HER2 addiction status in HER2-positive breast cancer",
abstract = "Despite different molecular tumor profiles indicate that human epidermal growth factor receptor 2 (HER2) messenger RNA (mRNA) levels mirror HER2 addiction and trastuzumab benefit in HER2-positive breast cancer (BC), the identification of noninvasive clinical predictors of trastuzumab sensitivity remains an unmet clinical need. In the current study, we investigated whether intratumor lactate levels reflect HER2 addiction and, in turn, trastuzumab susceptibility. Accordingly, the gene expression profiles of transgenic murine BC cell lines expressing the human d16HER2 variant (HER2-addicted) or human full-length HER2 (WTHER2; HER2-nonaddicted) revealed a significant enrichment of glycolysis-related gene pathways in HER2-addicted cells. We studied the metabolic content of 22 human HER2-positive BC by quantitative nuclear magnetic resonance spectroscopy and found that those cases with higher lactate levels were characterized by higher HER2 transcript levels. Moreover, gene expression analyses of HER2-positive BC samples from a TCGA data set revealed a significant enrichment in glycolysis-related pathways in high/HER2-addicted tumors. These data were confirmed by metabolic analyses of human HER2-positive BC cell lines with high or low HER2 transcript levels, which revealed significantly more active glycolytic metabolism in high HER2 transcript than in low HER2 transcript cells. Overall, our results provide evidence for noninvasive intratumor lactate detection as a potential metabolic biomarker of HER2 addiction and trastuzumab response suggesting the possibility to use in vivo imaging to assess lactate levels and, in turn, select HER2-positive BC patients who are more likely to benefit from anti-HER2 treatments.",
keywords = "breast cancer, glycolysis, HER2, lactate, oncogene addiction",
author = "Lorenzo Castagnoli and Egidio Iorio and Matteo Dugo and Ada Koschorke and Simona Faraci and Rossella Canese and Patrizia Casalini and Patrizia Nanni and Claudio Vernieri and {Di Nicola}, Massimo and Daniele Morelli and Elda Tagliabue and Pupa, {Serenella M.}",
year = "2019",
month = "2",
day = "1",
doi = "10.1002/jcp.27049",
language = "English",
volume = "234",
pages = "1768--1779",
journal = "Journal of Cellular Physiology",
issn = "1097-4652",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Intratumor lactate levels reflect HER2 addiction status in HER2-positive breast cancer

AU - Castagnoli, Lorenzo

AU - Iorio, Egidio

AU - Dugo, Matteo

AU - Koschorke, Ada

AU - Faraci, Simona

AU - Canese, Rossella

AU - Casalini, Patrizia

AU - Nanni, Patrizia

AU - Vernieri, Claudio

AU - Di Nicola, Massimo

AU - Morelli, Daniele

AU - Tagliabue, Elda

AU - Pupa, Serenella M.

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Despite different molecular tumor profiles indicate that human epidermal growth factor receptor 2 (HER2) messenger RNA (mRNA) levels mirror HER2 addiction and trastuzumab benefit in HER2-positive breast cancer (BC), the identification of noninvasive clinical predictors of trastuzumab sensitivity remains an unmet clinical need. In the current study, we investigated whether intratumor lactate levels reflect HER2 addiction and, in turn, trastuzumab susceptibility. Accordingly, the gene expression profiles of transgenic murine BC cell lines expressing the human d16HER2 variant (HER2-addicted) or human full-length HER2 (WTHER2; HER2-nonaddicted) revealed a significant enrichment of glycolysis-related gene pathways in HER2-addicted cells. We studied the metabolic content of 22 human HER2-positive BC by quantitative nuclear magnetic resonance spectroscopy and found that those cases with higher lactate levels were characterized by higher HER2 transcript levels. Moreover, gene expression analyses of HER2-positive BC samples from a TCGA data set revealed a significant enrichment in glycolysis-related pathways in high/HER2-addicted tumors. These data were confirmed by metabolic analyses of human HER2-positive BC cell lines with high or low HER2 transcript levels, which revealed significantly more active glycolytic metabolism in high HER2 transcript than in low HER2 transcript cells. Overall, our results provide evidence for noninvasive intratumor lactate detection as a potential metabolic biomarker of HER2 addiction and trastuzumab response suggesting the possibility to use in vivo imaging to assess lactate levels and, in turn, select HER2-positive BC patients who are more likely to benefit from anti-HER2 treatments.

AB - Despite different molecular tumor profiles indicate that human epidermal growth factor receptor 2 (HER2) messenger RNA (mRNA) levels mirror HER2 addiction and trastuzumab benefit in HER2-positive breast cancer (BC), the identification of noninvasive clinical predictors of trastuzumab sensitivity remains an unmet clinical need. In the current study, we investigated whether intratumor lactate levels reflect HER2 addiction and, in turn, trastuzumab susceptibility. Accordingly, the gene expression profiles of transgenic murine BC cell lines expressing the human d16HER2 variant (HER2-addicted) or human full-length HER2 (WTHER2; HER2-nonaddicted) revealed a significant enrichment of glycolysis-related gene pathways in HER2-addicted cells. We studied the metabolic content of 22 human HER2-positive BC by quantitative nuclear magnetic resonance spectroscopy and found that those cases with higher lactate levels were characterized by higher HER2 transcript levels. Moreover, gene expression analyses of HER2-positive BC samples from a TCGA data set revealed a significant enrichment in glycolysis-related pathways in high/HER2-addicted tumors. These data were confirmed by metabolic analyses of human HER2-positive BC cell lines with high or low HER2 transcript levels, which revealed significantly more active glycolytic metabolism in high HER2 transcript than in low HER2 transcript cells. Overall, our results provide evidence for noninvasive intratumor lactate detection as a potential metabolic biomarker of HER2 addiction and trastuzumab response suggesting the possibility to use in vivo imaging to assess lactate levels and, in turn, select HER2-positive BC patients who are more likely to benefit from anti-HER2 treatments.

KW - breast cancer

KW - glycolysis

KW - HER2

KW - lactate

KW - oncogene addiction

UR - http://www.scopus.com/inward/record.url?scp=85052376378&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052376378&partnerID=8YFLogxK

U2 - 10.1002/jcp.27049

DO - 10.1002/jcp.27049

M3 - Article

C2 - 30132876

AN - SCOPUS:85052376378

VL - 234

SP - 1768

EP - 1779

JO - Journal of Cellular Physiology

JF - Journal of Cellular Physiology

SN - 1097-4652

IS - 2

ER -